aggressive B-cell non-Hodgkin lymphoma
diseaseOn this page
Also known as aggressive B-cell NHL
Summary
aggressive B-cell non-Hodgkin lymphoma (MONDO:0017595) is a cancer (an umbrella term covering 6 Mondo subtypes) and 9 clinical trials. Top therapeutic interventions include rituximab, acalabrutinib, and epcoritamab. A subtype of B-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Umbrella term: 6 Mondo subtypes
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | aggressive B-cell non-Hodgkin lymphoma |
| Mondo ID | MONDO:0017595 |
| Orphanet | 300846 |
| NCIT | C178541 |
| UMLS | C5555120 |
| MedGen | 1791561 |
| GARD | 0021245 |
| Is cancer (heuristic) | yes |
Also known as: aggressive B-cell NHL
Disease family
This is a subtype of B-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › B-cell non-Hodgkin lymphoma › aggressive B-cell non-Hodgkin lymphoma
Related subtypes (4): B-cell acute lymphoblastic leukemia, indolent B-cell non-Hodgkin lymphoma, plasma cell leukemia, central nervous system non-hodgkin lymphoma
Subtypes (6): Burkitt lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement, mantle cell lymphoma, diffuse large B-cell lymphoma, B-cell prolymphocytic leukemia, precursor B-cell acute lymphoblastic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 3 |
| PHASE2 | 3 |
| Not specified | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03625037 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma |
| NCT05025800 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma |
| NCT05202782 | PHASE2 | ACTIVE_NOT_RECRUITING | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin’s Lymphoma or Transformed Indolent B-cell Lymphoma |
| NCT05583149 | PHASE2 | ACTIVE_NOT_RECRUITING | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas |
| NCT06834373 | PHASE2 | RECRUITING | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy |
| NCT07432022 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma |
| NCT06544265 | PHASE1 | RECRUITING | SynKIR-310 for Relapsed/Refractory B-NHL |
| NCT04870853 | Not specified | UNKNOWN | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy |
| NCT05840289 | Not specified | UNKNOWN | A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RITUXIMAB | 4 | 3 |
| ACALABRUTINIB | 4 | 1 |
| EPCORITAMAB | 4 | 1 |
| ZANUBRUTINIB | 4 | 1 |
| GOLCADOMIDE | 3 | 1 |
| LISOCABTAGENE MARALEUCEL | 3 | 1 |
| CHEMBL5193128 | 0 | 1 |
| CHEMBL4747506 | 0 | 1 |
| CHEMBL5187554 | 0 | 1 |
| CHEMBL5276925 | 0 | 1 |